IL23R and hepatocellular carcinoma: Inflammation in hepatocellular carcinoma (HCC) is a key factor in treatment resistance and understanding IL-23R's impact could provide insights into patient variability in drug response, potentially improving Sorafenib efficacy and enhancing treatment outcomes [16].